What You Should Know:
– Today, Talis Biomedical Corporation announced it has been awarded a $25M contract from the National Institutes of Health (NIH) as part of Phase 2 of its Rapid Acceleration of Diagnostics (RADx) initiative as well as another $100 million in additional financing.
– The new funding will be used to scale manufacturing for the launch of the Talis One™ diagnostic platform that provides rapid and highly accurate detection of COVID-19 at points-of-care in 30 minutes or less.
– The Talis One System is a fast, easy-to-use, solution that brings testing out of the lab and to the point of care. The technology provides healthcare professionals with an entire clinical lab in the palm of their hand and is intended for use in non-laboratory settings, such as physicians’ offices, urgent care clinics, elder care/assisted living facilities, cancer treatment and dialysis centers, and potentially the workplace.
Talis Biomedical Corporation, a company dedicated to developing high-performance point-of-care diagnostic tests for infectious diseases, today announced that it has secured a $25 million contract from the National Institutes of Health (NIH) for Phase 2 of its Rapid Acceleration of Diagnostics (RADx) initiative. Additionally, the company has completed an additional financing of $100 million to scale manufacturing for the launch of the Talis One™ diagnostic platform, which provides rapid and highly accurate detection of COVID-19 at the point-of-care.
Accurate Point of Care COVID-19 Testing
Today, patients are often forced to endure days of waiting for lab results. As a result, doctors may initiate unnecessary isolation or empirical treatment based on incomplete information. This approach is costly and can be harmful to patients. With COVID-19 cases on the rise in many areas across the country, there is a tremendous need for access to testing, especially in vulnerable populations where the spread of COVID-19 infection can be devastating. The Talis One System is a molecular diagnostic platform developed to enable rapid, highly accurate point-of-care testing for infectious diseases such as COVID-19.
Talis One COVID-19 Assays
The Talis One assays are based on a proprietary, highly optimized nucleic acid isothermal amplification chemistry to achieve exceptional test performance much faster than traditional PCR. The system is designed for use in non-laboratory settings, such as physicians’ offices, urgent care clinics, elder care/assisted living facilities, cancer treatment and dialysis centers, and potentially the workplace.
COVID-19 is the first infectious disease that the Talis One System will support. Future infectious disease indications may include assays for other respiratory infections, such as influenza, as well as sexually transmitted infections (STIs) and other infections impacting women’s health. The Talis One instrument can be managed remotely and sends test results to a cloud database for secure transmission, storage and review. Results are available in 30 minutes or less.
“We are extremely proud that the NIH selected Talis, out of a field of 600 applicants, to be among the first teams to move to the final phase of the RADx initiative. This important funding will accelerate the commercialization of our Talis One System for the detection of COVID-19. Additionally, we are pleased to have the continued support of our investors, who share our excitement about the significant impact the Talis One System can deliver as a fast and reliable diagnostic testing platform for life-threatening and life-altering infectious diseases,” said Brian Coe, Co-Founder and Chief Executive Officer of Talis.
“In response to the significant need for rapid, highly accurate testing solutions to help combat the pandemic, we were able to utilize our Talis One System, which we have been developing for clinical use in women’s health, to quickly develop an assay for SARS-CoV-2, the novel coronavirus that causes COVID-19. We are particularly focused on serving vulnerable populations, such as those in elder care facilities or patients with impaired immune systems. With the support of the NIH RADx program and proceeds from the new financing, we are confident that we will be able to accelerate our goal of making rapid diagnostic testing widely available,” added Coe.
NIH Support
The Talis One COVID-19 assay project is supported by the RADx program and has been funded in whole or in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92020C00010.
